Australia's most trusted
source of pharma news
Sunday, 28 April 2024
Posted 26 March 2024 AM
The TGA has handed out pathways for three innovative drugs, hinting at upcoming filings for Amgen, Norgine and Specialised Therapeutics.
Among the newcomers are two oncology candidates, including Amgen's potential first-in-class DLL3 bispecific T-cell engager therapy tarlatamab for small cell lung cancer (SCLC), which has been granted orphan status.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.